# Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease

> **NCT04552262** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 7 (actual)

## Conditions studied

- Moderate Chronic Kidney Disease

## Interventions

- **DRUG:** BAY2327949
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04552262
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-30
- **Primary completion:** 2020-12-21
- **Final completion:** 2021-05-05
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Terminated
- **Last updated:** 2022-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04552262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04552262, "Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04552262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*